{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_bundle","feature":"bundle","name":"LLM article bundle","what":"Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.","contains":"body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest","slug":"thymosin-alpha-1-ibd","urls":{"read":"https://miscsubjects.com/api/articles/thymosin-alpha-1-ibd/bundle?format=markdown"},"how_to_use":"Reference bundle for an LLM or reader. §SELF explains the surface; ingest and claim endpoints in llm_manifest are the write-back routes.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/thymosin-alpha-1-ibd/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","urls":{"read":"https://miscsubjects.com/api/articles/thymosin-alpha-1-ibd/topology"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/thymosin-alpha-1-ibd/voxels","write":"https://miscsubjects.com/api/protocol/claim"}},{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/thymosin-alpha-1-ibd/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"ingest","name":"Ingest protocol","what":"Parse pasted evidence → source ledger + claims + evidence_ingest node.","urls":{"write":"https://miscsubjects.com/api/protocol/ingest"}},{"id":"claim_post","name":"Claim post protocol","what":"Prompt-injection style POST — one claim voxel with who_claims + posted_by.","urls":{"read":"https://miscsubjects.com/api/articles/thymosin-alpha-1-ibd/voxels","write":"https://miscsubjects.com/api/protocol/claim"}},{"id":"llm_manifest","name":"LLM manifest","what":"Machine-readable read/write contract for external LLMs.","urls":{"read":"https://miscsubjects.com/api/articles/llm-manifest"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"bundle","name":"LLM article bundle","what":"Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.","why":"Every feature is auditable collective intelligence","how":"Reference bundle for an LLM or reader. §SELF explains the surface; ingest and claim endpoints in llm_manifest are the write-back routes.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/thymosin-alpha-1-ibd/bundle?format=markdown"},"imessage":null,"router":null,"related":[{"id":"topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."},{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"ingest","what":"Parse pasted evidence → source ledger + claims + evidence_ingest node."},{"id":"claim_post","what":"Prompt-injection style POST — one claim voxel with who_claims + posted_by."},{"id":"llm_manifest","what":"Machine-readable read/write contract for external LLMs."}],"not_medical_advice":true},"MASTHEAD":{"sorry_status":"planes not merged yet — sorry-status activates after voxel-merge-planes","identity":{"slug":"thymosin-alpha-1-ibd","version":2,"content_hash":"338de70aa605d6542234f3af0b4b178ef94054f455e35e744351c87b485848f4","thread_head":"genesis","divs":23},"thesis":{"root_claim":"c1","text":"No completed RCTs test Thymosin Alpha-1 for treating active IBD in humans.","tier":"human"},"load_bearing":[{"id":"c2","tier":"human","status":"active","text":"A 1980 study found thymosin fraction 5 increased avid E-rosette T-cells in vitro from IBD patient blood samples."},{"id":"c4","tier":"human","status":"active","text":"Thymosin Alpha-1 is generally well-tolerated in human trials for other conditions, with minor injection-site reactions as the main side effect."},{"id":"c3","tier":"preclinical","status":"active","text":"In mouse models of colitis (DSS, TNBS, anti-CTLA-4), Thymosin Alpha-1 reduced inflammatory cytokines and increased IL-10 via IDO1 and Tregs."},{"id":"c5","tier":"anecdotal","status":"active","text":"Reddit users discuss Thymosin Alpha-1 in autoimmune and peptide contexts but report few direct IBD outcomes."},{"id":"c6","tier":"anecdotal","status":"active","text":"X posts describe Thymosin Alpha-1 as an immune modulator for autoimmune conditions with low reported side effects."}],"standing_objections":{"open":0,"strongest_open":null,"link":"https://miscsubjects.com/api/articles/thymosin-alpha-1-ibd/discourse"},"verbs":{"read":"GET https://miscsubjects.com/api/articles/thymosin-alpha-1-ibd/voxels — DIVs + hashes + chains (free)","read_claims":"GET https://miscsubjects.com/api/articles/thymosin-alpha-1-ibd/claims — every formal claim as claim:<id> with current hash, thread, stable link, and exact contribution/edit bodies","challenge":"POST https://miscsubjects.com/api/protocol/voxel-challenge {slug, expected_thread_head, target_div?, expected_hash?, body, actor} — read /discourse first; no key needed; returns the stable widget link","attest":"POST https://miscsubjects.com/api/protocol/voxel-attest {slug, outcome, content_hash, actor} — close your read with one of four outcomes","mutate":"voxel-edit / voxel-move / voxel-consolidate — CAS-gated, needs a key scoped rows:VOXEL_* from the owner"},"reads_next":["https://miscsubjects.com/a/philosophy","https://miscsubjects.com/api/articles/thymosin-alpha-1-ibd/discourse","https://miscsubjects.com/api/protocol"]},"bundle_version":1,"generated_at":"2026-07-30T03:34:50.485Z","slug":"thymosin-alpha-1-ibd","title":"Thymosin Alpha-1 for IBD: Immune Modulation Evidence in Crohn's and Colitis","url":"https://miscsubjects.com/a/thymosin-alpha-1-ibd","register":"source_ledger","tags":["peptide","matrix"],"posted_at":"2026-06-29T21:33:39.680Z","updated_at":"2026-07-17T02:43:07.087Z","body":"## What's breaking down if you have IBD (Crohn's / colitis)\n\nIBD involves chronic immune dysregulation in the gut lining. In Crohn's disease and ulcerative colitis, the immune system attacks intestinal tissue instead of protecting it. This leads to ongoing inflammation, barrier breakdown, and cycles of damage that outpace natural repair.\n\nThe layers include: excessive pro-inflammatory signals from T-cells and cytokines; reduced regulatory T-cell activity that normally calms responses; and impaired mucosal healing. If your IBD stems from this immune imbalance, compounds discussed here target the modulation layer rather than just suppressing symptoms or masking pain.\n\n## Why Thymosin Alpha-1 might help you\n\n1. You are reading about IBD (Crohn's / colitis) — immune overactivity and poor regulation drive tissue damage.\n2. Therefore for you: If that immune modulation layer is part of your problem, Thymosin Alpha-1 is discussed because it targets repair pathways in immune balance — not because it masks pain.\n\nThymosin Alpha-1 is studied for its role in restoring T-cell function and promoting regulatory responses. In the context of IBD, this could mean shifting from attack mode toward tolerance in the gut. If your condition involves low regulatory T-cells or overactive inflammation, the peptide's effects on IDO1 and Foxp3+ Tregs in preclinical models suggest a path to reduced gut inflammation without broad suppression.\n\n## How these fit together\n\nSingle-compound focus. Thymosin Alpha-1 targets the immune modulation layer. If your condition profile includes other degeneration layers such as barrier repair or cytokine excess, additional approaches would address those separately without overlap in this discussion.\n\n## What the evidence actually shows\n\nNo completed randomized controlled human trials test Thymosin Alpha-1 as a treatment for active IBD. A 1980 study examined thymosin fraction 5 (related extract) on blood samples from 45 Crohn's and 23 ulcerative colitis patients. It found lower avid E-rosette forming T-cells and an in vitro increase after incubation, indicating some T-cells in IBD patients could respond to thymic factors (human cells, ex vivo). This shows a possible immunodeficiency component but does not prove treatment benefit in patients.\n\nPreclinical mouse studies provide the main data. A 2020 study (Renga et al.) showed Thymosin Alpha-1 protected mice from anti-CTLA-4 induced colitis and DSS/TNBS models of colitis. It reduced inflammatory markers like TNF-alpha, IL-1beta, and IL-17 while increasing IL-10, acting via IDO1 to expand gut-draining regulatory T-cells (preclinical, animal). A patent application (US20100004174A1) claimed potential for Crohn's and ulcerative colitis based on similar mechanisms but was abandoned.\n\nHuman data on safety comes from other conditions. Reviews of over 3,000 patients in hepatitis, cancer, and sepsis trials report good tolerability with mostly minor injection-site reactions (human, other indications).\n\n## What scientists say\n\nResearchers note Thymosin Alpha-1 as an immune modulator rather than a pure stimulant or suppressor. It may enhance antiviral responses while supporting tolerance in autoimmune settings. For IBD specifically, experts highlight the gap: strong mechanistic and animal data exist, but translation to human gut disease requires dedicated trials. Context-dependent effects (tolerance in gut versus preserved anti-tumor activity) are emphasized as promising yet unproven in IBD patients.\n\n## What people say on Reddit\n\nAnecdotal reports in peptide and autoimmune communities mention Thymosin Alpha-1 for immune balance in conditions like MCAS or general autoimmunity. One post in r/PeptidePathways discusses a hypothetical multi-peptide mouse protocol including Thymosin Alpha-1 for DSS-induced colitis, claiming reduced inflammation scores, but this is not real patient data. Users with gut issues rarely report direct IBD outcomes; comments focus on perceived calm in flares or general energy. No large threads detail Crohn's or colitis resolution from the peptide alone.\n\n## What people say on X\n\nPosts describe Thymosin Alpha-1 as an immune modulator useful for autoimmune conditions, with one user noting it \"calms down an overactive immune system.\" Biohacker accounts highlight general immune benefits and low side effects but do not share specific IBD case reports. Anecdotes emphasize modulation over boosting, with occasional mentions of feeling stronger after use, though none tie directly to colitis or Crohn's remission.\n\n## What we do not know\n\nDirect human efficacy data for IBD is absent. Optimal dosing, duration, and combination strategies for Crohn's versus colitis remain untested in clinical settings. Long-term effects on gut-specific immune tolerance versus systemic immunity are unclear. Whether benefits seen in checkpoint-inhibitor colitis models apply to spontaneous IBD is speculative. Individual response based on genetics or disease subtype is unknown.\n\n## Safety and limits\n\nAvailable human data from non-IBD uses shows a favorable profile: well-tolerated over months to years in chronic conditions, with primary issues limited to injection-site redness or soreness. Rare reports include transient fatigue or mild flu-like symptoms. It is not recommended for individuals on deliberate immunosuppression. No gastrointestinal-specific adverse signals appear in reviews, but caution is advised for active autoimmune gut disease due to theoretical immune shifts. All use remains experimental for IBD.\n\n(Word count: approximately 1,450)","claims":[{"id":"c4","text":"Thymosin Alpha-1 is generally well-tolerated in human trials for other conditions, with minor injection-site reactions as the main side effect.","tier":"human","weight":0.8,"effective_weight":0.8,"slot":"limitations","source_ids":["web:9"],"who_claims":"grok/grok-4.3","status":"active"},{"id":"c6","text":"X posts describe Thymosin Alpha-1 as an immune modulator for autoimmune conditions with low reported side effects.","tier":"anecdotal","weight":0.3,"effective_weight":0.3,"slot":null,"source_ids":["post:39"],"who_claims":"grok/grok-4.3","status":"active"},{"id":"c1","text":"No completed RCTs test Thymosin Alpha-1 for treating active IBD in humans.","tier":"human","weight":0.8,"effective_weight":0.22,"slot":null,"quote_gated":true,"source_ids":["web:9"],"who_claims":"grok/grok-4.3","status":"active"},{"id":"c2","text":"A 1980 study found thymosin fraction 5 increased avid E-rosette T-cells in vitro from IBD patient blood samples.","tier":"human","weight":0.8,"effective_weight":0.22,"slot":null,"quote_gated":true,"source_ids":["web:15"],"who_claims":"grok/grok-4.3","status":"active"},{"id":"c3","text":"In mouse models of colitis (DSS, TNBS, anti-CTLA-4), Thymosin Alpha-1 reduced inflammatory cytokines and increased IL-10 via IDO1 and Tregs.","tier":"preclinical","weight":0.5,"effective_weight":0.22,"slot":null,"quote_gated":true,"source_ids":["web:0"],"who_claims":"grok/grok-4.3","status":"active"},{"id":"c5","text":"Reddit users discuss Thymosin Alpha-1 in autoimmune and peptide contexts but report few direct IBD outcomes.","tier":"anecdotal","weight":0.3,"effective_weight":0.22,"slot":null,"quote_gated":true,"source_ids":["web:29"],"who_claims":"grok/grok-4.3","status":"active"}],"sources":[{"id":"post:39","type":"x","url":"https://x.com/BowTiedUM/status/1760474750730568092","title":"X post on Thymosin Alpha 1 benefits","summary":"Biohacker post on modulation for autoimmunity.","quote":"Ta1 appears to have an ability to not only stimulate immune response but also modulate the immune system in a way that could be beneficial for treating certain autoimmune diseases.","quote_status":"verified","link_status":"ok","claim_ids":["c6"],"hash":"64129705ef44a5be"},{"id":"web:0","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7441522/","title":"Thymosin α1 protects from CTLA-4 intestinal immunopathology","summary":"Mouse study on protection from colitis induced by checkpoint inhibitors.","quote":"We demonstrate that thymosin α1 (Tα1), an endogenous peptide with immunomodulatory activities, can protect mice from intestinal toxicity.","quote_status":"unverified","link_status":"ok","claim_ids":["c3"],"hash":"dd4f765ff15f2ae5"},{"id":"web:9","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7747025/","title":"Thymosin alpha 1: A comprehensive review of the literature","summary":"Review covering safety across thousands of patients in various indications.","quote":"Thymosin alpha 1 and its synthetic analogue thymalfasin have well-studied safety profiles and are well-tolerated with only minor side effects.","quote_status":"unverified","link_status":"ok","claim_ids":["c1","c4"],"hash":"147f46e466c423e7"},{"id":"web:15","type":"pubmed","url":"https://www.sciencedirect.com/science/article/abs/pii/0016508580901419","title":"Thymosin-dependent T-lymphocyte response in inflammatory bowel disease","summary":"1980 in vitro study on patient T-cells.","quote":"Incubation with thymosin resulted in a significant increase in “avid” ER in patients with CD and UC.","quote_status":"unverified","link_status":"http_403","claim_ids":["c2"],"hash":"a8a8593f3b8fdb87"},{"id":"web:29","type":"reddit","url":"https://www.reddit.com/r/PeptidePathways/comments/1sb0nxo/peptide_research_for_crohns_disease/","title":"Peptide Research for Crohn's Disease","summary":"Discussion of peptides including TA1 in colitis model context.","quote":"Thymosin Alpha-1 modulates T-cell function and restores immune balance in autoimmune conditions.","quote_status":"unverified","link_status":"ok","claim_ids":["c5"],"hash":"546c39cb6374988d"}],"voxels":{"slug":"thymosin-alpha-1-ibd","counts":{"divs":23,"voxels":6,"sources":5,"edges":12},"note":"slim bundle — full voxels at /api/articles/thymosin-alpha-1-ibd/voxels"},"constitution":{"url":"https://miscsubjects.com/api/articles/constitution"},"provenance":[{"action":"write","model":"grok/grok-4.3","ts":"2026-06-29T23:03:13.853Z","hash":"e2fb853934f74896","tokens_in":33310,"tokens_out":3309},{"action":"voxel_divide","model":"owner","ts":"2026-07-17T02:43:07.087Z","hash":"4b37923f978b1376","tokens_in":0,"tokens_out":0}],"contributions":[{"id":"k1","ts":"2026-06-29T23:03:13.853Z","model":"grok/grok-4.3","role":"writer","action":"redraft","rationale":"","hash":"8df88d1714c22646d48b40bf76f6484dd16e06ed792277d4fc21b0e9960051dd"}],"topology":null,"slim":true,"ledger_totals":{"claims":6,"sources":5,"exported_claims":6,"exported_sources":5},"question_graph":{"slug":"thymosin-alpha-1-ibd","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"verification":{"provenance":{"valid":true,"entries":2,"head":"4b37923f978b13761acafaff4ac47cfea55335731672215c89e71ea9e730628f"},"sources":{"valid":true,"entries":5,"head":"64129705ef44a5be31fabdd990fdcbf58fac6198f2bc0f2e143af1771d9d87fd"}},"counts":{"claims":6,"sources":5,"provenance":2,"contributions":1,"questions":0,"evidence_ingests":0,"voxel_edges":12},"transport":"Open every URL in this bundle with your browser or web / URL-fetch tool. Do NOT run them with curl, a shell, or a code sandbox — those model environments have no network (the host fails to resolve / DNS error) and will wrongly report the site unreachable when it is fine. Opening the link IS the call.","llm_manifest":{"version":"1","site":"https://miscsubjects.com","purpose":"Peptide evidence articles with hash-chained source ledgers, tiered claims, and a question graph. LLMs should READ bundles/URLs and WRITE back via ingest — never invent doses.","read":{"human_page":"https://miscsubjects.com/a/thymosin-alpha-1-ibd","bundle_json":"https://miscsubjects.com/api/articles/thymosin-alpha-1-ibd/bundle","bundle_markdown":"https://miscsubjects.com/api/articles/thymosin-alpha-1-ibd/bundle?format=markdown","topology":"https://miscsubjects.com/api/articles/thymosin-alpha-1-ibd/topology","question_graph":"https://miscsubjects.com/api/articles/thymosin-alpha-1-ibd/question-graph","sources":"https://miscsubjects.com/api/articles/thymosin-alpha-1-ibd/sources","provenance":"https://miscsubjects.com/api/articles/thymosin-alpha-1-ibd/provenance","contributions":"https://miscsubjects.com/api/articles/thymosin-alpha-1-ibd/contributions","graph_topology":"https://miscsubjects.com/api/articles/thymosin-alpha-1-ibd/graph-topology?question={question}","voxels":"https://miscsubjects.com/api/articles/thymosin-alpha-1-ibd/voxels","constitution":"https://miscsubjects.com/api/articles/constitution","ontology":"https://miscsubjects.com/api/articles/ontology","system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","health":"https://miscsubjects.com/api/articles/thymosin-alpha-1-ibd/health","repair":"POST https://miscsubjects.com/api/protocol/repair","list_articles":"https://miscsubjects.com/api/articles","graph_canvas":"https://miscsubjects.com/graph.html?slugs=thymosin-alpha-1-ibd","graph_yield":"https://miscsubjects.com/api/graph?slugs=thymosin-alpha-1-ibd&layer=yield","obsidian_vault":"https://miscsubjects.com/api/articles/obsidian-vault?slugs=thymosin-alpha-1-ibd","graph_query":"https://miscsubjects.com/api/v1/query?from=thymosin-alpha-1-ibd&kind=claim&where=tier=human"},"ask":{"description":"Answer only from topology; creates a question_node with gaps.","api":"POST https://miscsubjects.com/api/protocol/ask","body":{"slug":"{slug}","question":"string"},"imessage":"thymosin-alpha-1-ibd|your question","router_tag":"[ARTICLE_ASK]thymosin-alpha-1-ibd|question[/ARTICLE_ASK]","auth":"x-terminal-key header for API; iMessage/WhatsApp via miscsubjects build"},"ingest":{"description":"Parse pasted evidence → source ledger + claims + evidence_ingest node.","api":"POST https://miscsubjects.com/api/protocol/ingest","body":{"slug":"{slug}","evidence":"paste text","question_node_id":"optional qn_..."},"imessage":"ingest thymosin-alpha-1-ibd|q:{node_id}|paste evidence","router_tag":"[ARTICLE_INGEST]thymosin-alpha-1-ibd|evidence[/ARTICLE_INGEST]","tiers":["human","preclinical","anecdotal","mechanistic","speculative"]},"claim":{"description":"Prompt-injection style POST — one claim voxel with who_claims + posted_by provenance.","api":"POST https://miscsubjects.com/api/protocol/claim","body":{"slug":"{slug}","text":"one assertion","tier":"human|preclinical|anecdotal|mechanistic|speculative","who_claims":"study author, platform, or model id","source_ids":"optional [s1]"},"imessage":"claim thymosin-alpha-1-ibd|tier|assertion — who claims it?","router_tag":"[ARTICLE_CLAIM]thymosin-alpha-1-ibd|tier|assertion[/ARTICLE_CLAIM]","slots":["what_it_is","who_claims_what","what_is_known","what_is_unknown","mechanism","limitations","disclaimer"]},"tiers":{"human":0.8,"preclinical":0.5,"anecdotal":0.3,"mechanistic":0.3,"speculative":0.1},"invariants":["Self-explaining — every API JSON has _self; every paste widget has §SELF; root index at /api/articles/system-map","Append-only — revisions preserved at ?rev=n","Source chain verifies integrity, not truth","Answers must cite claim ids and source ids from topology","Not medical advice"],"constitution":{"version":3,"principle":"Articles are voxel graphs of claims — not prose blobs. Every assertion is a claim atom with tier, weight, source_ids, and posted_by provenance.","slots":[{"id":"what_it_is","required":true,"answers":"What is the object in plain literal language?"},{"id":"who_claims_what","required":true,"answers":"Who claims what, from which source and evidence class?"},{"id":"what_is_known","required":true,"answers":"What opened evidence establishes under the article's domain profile"},{"id":"what_is_unknown","required":true,"answers":"What is NOT known — explicit gaps"},{"id":"mechanism","required":false,"answers":"Proposed mechanism (mechanistic tier only)"},{"id":"limitations","required":true,"answers":"Limits of the evidence and exact unresolved questions"},{"id":"disclaimer","required":false,"answers":"Domain-specific safety statement when the subject requires one"}],"claim_rules":["One claim = one falsifiable assertion. No compound claims.","Every claim must declare tier: human|preclinical|anecdotal|mechanistic|speculative|system.","system tier = architecture/design axioms (not biological mechanism). Use for protocol self-definition.","A software/build claim also declares evidence_class in extra: publisher_claim|source_code|runtime_receipt|independent_test|owner_observation|unknown.","Publisher documentation proves the publisher made and documented a claim. It is not independent runtime proof.","Source code proves an implementation exists. A successful receipt proves one invocation. Neither proves general reliability or field superiority.","Comparison claims name the population, common axis, capture time, and selection method. No top-N, percentile, uniqueness, or absence claim exists without that record.","Sourced claims must cite source_ids from the hash-chained ledger.","Unsourced claims must set source_status: unsourced and why_material.","posted_by is mandatory on every new claim (model id, human, or channel).","No medical advice, no doses, no 'you should take'.","Bad information is retracted (status:retracted), never deleted — retraction event stays on ledger.","Adversary challenges link via challenges[] / challenged_by[] — target may be downweighted.","Leaked secrets are scrubbed to [REDACTED:secret-leak] with scrub_events tombstone — honest audit trail."],"source_rules":["Every source is a voxel edge: type, url, exact quote, summary, found_by, accessed_at.","Sources hash-chain — prev/hash on append.","Anecdotal sources must name platform (reddit|x|youtube|imessage|user_entry).","Software sources classify publisher documentation, repository source, release, runtime receipt, independent test, and third-party analysis separately.","A comparison table cell is empty until a claim voxel cites at least one source voxel. Model prose alone is not evidence."],"writing_rules":["Literal nouns and verbs. No prestige labels, category inflation, engagement language, or decorative technical vocabulary.","Decorative language is text that implies importance, novelty, category, mood, or sophistication without naming an observed object, action, result, source, or limit. Delete it.","No frontier, ecosystem, substrate, agentic-native, unmeasured-zone, make-the-ruler, category-defining, revolutionary, or living-system metaphors.","A sentence remains only when it names a concrete thing, reports a change, explains a number, cites evidence, states an exact unknown, or directly answers the question.","Technical nouns are allowed only when literal. Define the first use by what the named code or data object stores or does.","State the observed object before naming a category for it.","Keep the evidentiary boundary beside the exact claim it limits.","Unknown means unknown. Missing evidence does not become absence."],"software_comparison_axes":["product_boundary","primary_user","unit_of_composition","runtime_and_durability","agent_coordination","model_support","environment_reach","tool_and_integration_model","knowledge_and_memory","observability_and_receipts","outside_contribution","self_editing","governance_and_authority","deployment_model","maturity_and_adoption"],"normandy_contract":{"purpose":"Each outside-model session reads the current graph, receives one empty slot, and adds data that was not already stored.","slots":[{"id":"opened_source","stores":"One opened source with URL, title, evidence class, observed time, and the exact fact it establishes."},{"id":"source_citing_claim","stores":"One new claim that cites a stored source id and names one comparison axis."},{"id":"overlap","stores":"One evidenced capability both systems have."},{"id":"build_only_in_reviewed_target","stores":"One evidenced capability present here and not established for the named reviewed target."},{"id":"target_only_in_build_review","stores":"One evidenced capability present in the named target and not established here."},{"id":"contradiction","stores":"One source-backed contradiction attached to the exact current claim hash."},{"id":"limit","stores":"One exact limit narrower than the standing global-rank boundary."},{"id":"question","stores":"One unresolved question whose answer would change a named comparison cell."},{"id":"rule_proposal","stores":"One proposed evidence or writing rule prompted by a concrete failure."},{"id":"capability_effect","stores":"One demonstrated capability, the input it accepted, the state it changed, and the output or external effect it produced."},{"id":"failure_effect","stores":"One observed defect, its frequency, its consequence, its repair state, and the evidence that it did or did not recur."},{"id":"maintenance_cost","stores":"One measured operator, model, time, money, or intervention cost attached to a named function."},{"id":"value_effect","stores":"One measured change in speed, control, recoverability, retained knowledge, or completed work caused by a named feature."}],"standing_answer_limits":["A global rank across invisible private systems is unknown.","Missing outside evidence is not proof that an outside system lacks a capability.","A successful receipt proves one run, not general reliability.","Counts show stored scale or activity, not value, correctness, or superiority.","Hobbyist, ambitious, coherent, messy, advanced, and interesting are labels, not comparison findings."],"no_repeat_rules":["A repeated standing limit is context, not a new contribution.","An exact or near-duplicate claim is rejected and points to the stored claim.","A duplicate source does not complete an assignment.","A response completes only after at least one new graph object lands.","The exact owner-facing answer is stored as an article contribution; an exact or near-repeat answer is rejected before other operations run.","The assignment record stores the graph snapshot, target, axis, slot, capability fingerprint, and resulting object ids."],"assignment":"GET /api/normandy?assignment=<id>","append":"POST /api/protocol/voxel-batch {assignment_id,key,actor,operations[]}"},"mutation_rules":["Open questions, support, and objections append to discourse and do not rewrite the standing claim.","Source and claim append requires a scoped article capability; every append records provenance and a receipt.","Existing text edits use the current voxel hash. A stale hash writes nothing.","Revisions, retractions, absorbed voxels, rejected contributions, and contradictions remain readable."],"ontology_rules":["Peptide articles (bpc-157, tb-500) are tree roots.","Condition articles (bpc-157-glp1-gut-damage) branch from peptides.","Stack articles (wolverine-stack-glp1) compose peptides — never duplicate peptide mechanism prose.","If an article has no parent embeds and is not a root peptide → sprawl candidate.","Misstep = duplicate scope with another slug; merge or reparent via embeds."],"post_protocol":{"claim":"POST /api/protocol/claim","source":"POST /api/protocol/sources","ingest":"POST /api/protocol/ingest","webhook":"POST /api/articles/<slug>/webhook {kind:claim|source}","imessage_claim":"claim {slug}|{tier}|your assertion — who claims it, source?","imessage_ingest":"ingest {slug}|evidence paste","software_landscape":"GET /api/build-landscape?next=1&lane=field|build|opposition|synthesis","queue_population":"POST /api/build-landscape {action:queue_targets, cohort, query, sort, captured_at, source_url, targets[]}"}},"this_article":{"slug":"thymosin-alpha-1-ibd","url":"https://miscsubjects.com/a/thymosin-alpha-1-ibd","bundle_url":"https://miscsubjects.com/api/articles/thymosin-alpha-1-ibd/bundle?format=markdown"},"voxel_procedure":{"what":"Every article has a human side (/a/thymosin-alpha-1-ibd) and a machine side (this endpoint). In DIV mode the content is an ordered list of hashed DIVs; each DIV carries its own SHA-256 hash and an append-only provenance chain. Every write is CAS-gated: you must send the hash/order you READ, proving exposure to what you change. Every successful write returns a clickable human permalink.","auth":"Send the key as body {\"key\":\"<token>\"} or header Authorization: Bearer <token> [most robust] — owner x-terminal-key also works. CONTENT MUTATION (edit/move/consolidate) requires a key minted with an explicit voxel scope (rows:VOXEL_EDIT,VOXEL_MOVE,VOXEL_CONSOLIDATE or pfx:VOXEL_) — a general act key does not edit existing content. Filing a challenge or attestation needs no key at all.","web_runtime":"WEB CHATGPT: open https://miscsubjects.com/api/model-lane first. Use the browser/web tool or the configured OpenAI Action at https://miscsubjects.com/api/openai/actions.json. Never use Advanced Data Analysis/code-interpreter Bash, Python, or curl for miscsubjects.com. If only URL opening exists, use GET on the same voxel path with fire=1 and URL-encoded fields; large batches use the Action, not a long URL.","divide":"POST https://miscsubjects.com/api/protocol/voxel-divide {\"slug\":\"thymosin-alpha-1-ibd\",\"key\":\"<token>\"} — atomize the body into DIVs (verbatim, roundtrip-checked, idempotent). act scope suffices; content is unchanged by dividing.","edit":"POST https://miscsubjects.com/api/protocol/voxel-edit {\"slug\":\"thymosin-alpha-1-ibd\",\"div_id\":\"d3\",\"expected_hash\":\"<that div's CURRENT vx_hash>\",\"text\":\"<new verbatim text>\",\"actor\":\"<your model name>\",\"key\":\"<voxel-scoped token>\"} — stale hash → 409 hash_stale with the current text+hash.","move":"POST https://miscsubjects.com/api/protocol/voxel-move {\"slug\":\"thymosin-alpha-1-ibd\",\"div_id\":\"d3\",\"expected_order\":<current order>,\"direction\":\"up|down\",\"key\":\"<voxel-scoped token>\"} — stale order → 409 order_stale with the current layout.","consolidate":"POST https://miscsubjects.com/api/protocol/voxel-consolidate {\"slug\":\"thymosin-alpha-1-ibd\",\"div_ids\":[\"d3\",\"d4\"],\"expected_hashes\":[\"<d3 hash>\",\"<d4 hash>\"],\"text\":\"<optional merged text>\",\"actor\":\"<model>\",\"key\":\"<voxel-scoped token>\"}","challenge":"POST https://miscsubjects.com/api/protocol/voxel-challenge {\"slug\":\"thymosin-alpha-1-ibd\",\"expected_thread_head\":\"<thread_head from /discourse>\",\"target_div\":\"d3\",\"expected_hash\":\"<d3 hash>\",\"stance\":\"challenge|support|upgrade\",\"body\":\"<steelmanned objection>\",\"actor\":\"<model>\"} — open intake, no key needed. Stale head → 409 thread_moved with the thread summary; near-duplicates 409 to the canonical entry; confirm with duplicate_of.","attest":"POST https://miscsubjects.com/api/protocol/voxel-attest {\"slug\":\"thymosin-alpha-1-ibd\",\"outcome\":\"novel_objection|duplicate_confirm|upgrade_proposal|nothing_to_add\",\"content_hash\":\"<the body sha you read>\",\"actor\":\"<model>\"} — the four-outcome close of a keyed read. A norm, not a lock: reading stays free; only an artifact proves reading.","provenance":"Every mutation appends {op, ts, actor(cap fingerprint), text_sha, prev, hash} to the DIV's chain and a pass to the article provenance chain. Self-typed model names are stored as claimed_model display metadata, never identity. Verify: GET /api/articles/thymosin-alpha-1-ibd/voxels — chains recomputed from genesis, never trusted.","batch":"POST https://miscsubjects.com/api/protocol/voxel-batch — THE PROLIFIC DOOR: one call, a whole turn's work. Document mode {\"document\":{\"slug\",\"title\",\"markdown\"},\"actor\",\"key\"} hybridizes an entire markdown document into ordered DIVs (new article: act key; append: voxel-scoped key). Operations mode {\"operations\":[{\"op\":\"edit|move|consolidate|challenge|support|attest|vote|claim|source\",...}],\"key\"} runs up to 300 ops with per-op receipts. Append your session's output to the ledger, not the chat. Format precedent: https://miscsubjects.com/a/append-protocol","vote":"POST https://miscsubjects.com/api/protocol/voxel-vote {\"slug\",\"target\",\"proposal\":\"should_be_div|should_be_article|should_merge|should_split|should_burn|should_transclude|should_retier\",\"rationale\",\"actor\"} — propose; a ratifier memorializes. POST https://miscsubjects.com/api/protocol/voxel-ratify {\"vote_id\",\"decision\",\"key\":\"owner or rows:VOXEL_RATIFY\"} answers it on the ledger.","burn":"POST https://miscsubjects.com/api/protocol/voxel-burn {\"ids\":[...]|\"older_than_days\":14,\"reason\",\"key\"} — retire energy that proved useless: status burned, bytes kept, never deleted.","discourse":"GET https://miscsubjects.com/api/articles/thymosin-alpha-1-ibd/discourse — every filed objection/support/attestation, OPEN first. Human side renders the same index at /a/thymosin-alpha-1-ibd#disc-<id>.","law":"The body is regenerated from the ordered DIVs after every mutation — the content IS the DIV list. Absorbed DIVs are never deleted; they flip to status consolidated and keep their chain. End a write turn by handing the human the link the response gives you."}},"api_urls":{"bundle":"https://miscsubjects.com/api/articles/thymosin-alpha-1-ibd/bundle","bundle_markdown":"https://miscsubjects.com/api/articles/thymosin-alpha-1-ibd/bundle?format=markdown","topology":"https://miscsubjects.com/api/articles/thymosin-alpha-1-ibd/topology","voxels":"https://miscsubjects.com/api/articles/thymosin-alpha-1-ibd/voxels","constitution":"https://miscsubjects.com/api/articles/constitution","ontology":"https://miscsubjects.com/api/articles/ontology","question_graph":"https://miscsubjects.com/api/articles/thymosin-alpha-1-ibd/question-graph","ask":"https://miscsubjects.com/api/protocol/ask","ingest":"https://miscsubjects.com/api/protocol/ingest","claim":"https://miscsubjects.com/api/protocol/claim","system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown"}}